Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2100052494Phase 2Recruiting
Phase 2, open-label, single-arm trial of tucidinostat, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Complete remission rate. Started Nov 2021; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2100052494.